Additive Benefits of Control-IQ+ Automated Insulin Delivery (AID) to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
Primary result · HbA1c in GLP-1 RA usersResult — go to the resultMean improvement −0.5 % 95% CI −0.8 to −0.3Authors' conclusion
The benefits of AID appear to be substantial for a broad spectrum of insulin-treated patients with type 2 diabetes, including those already receiving contemporary and guideline-directed therapy, such as a GLP-1 RA medication. These additive benefits of AID in GLP-1 RA users included significant reductions in HbA1c levels with simultaneous reduction in insulin use, along with no statistical increase in weight despite very significant improvements in glycemic control.
Study context
- Population
- Adults with insulin-treated T2D using a GLP-1 RA at baseline, continued during the trialof 319 in trial
- Participants
- 143 adults
- Comparison
- Control-IQ+ AID vs continuation of prestudy insulin delivery plus CGM, in GLP-1 RA users
Methodological detailssubgroup analysis by GLP-1 RA use
- Subgroup analysis by GLP-1 RA use
Primary result
HbA1c in GLP-1 RA users
Mean improvement
−0.5 %
95% CI −0.8 to −0.3
P < 0.001
As reported in the abstract
- Mean HbA1c decrease with AID from baseline of 8.0 ± 1.2%
- 0.8%
Further findings
| Outcome | Difference (kg) (95% CI) | P value | |
|---|---|---|---|
| Weight in GLP-1 RA users · 13 weeks | 0.9 (−0.2 to 2.1) | P = 0.10 | |
| −10123Difference, kg (linear scale) |
| Outcome | Mean weight gain (kg) (95% CI) | P value |
|---|---|---|
| Weight in GLP-1 RA nonusersHigher with AID | 1.9 (0.5–3.2) | P = 0.007 |
TIR 70-180 mg/dL and other CGM hyperglycemia metrics in GLP-1 RA users
- Comparable statistically significant improvements with AID when added to GLP-1 RA
Original publication
Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes. Diabetes Care. Published 20 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →